[Experience with clinical use of the drug gammalon in children with cerebral palsy].
D000293:Adolescent; D000613:Aminobutyrates / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004576:Electromyography; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000150:complications; D007223:Infant; D008607:Intellectual Disability / Q000150:complications; D008297:Male; D009119:Muscle Contraction; D009135:Muscular Diseases / Q000139:chemically induced; D010264:Paraplegia / Q000188:drug therapy; D012026:Reflex, Stretch; D012893:Sleep Wake Disorders / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000613:Aminobutyrates; D005680:gamma-Aminobutyric Acid
Opyt klinicheskogo primeneniia preparata gammalon pri detskom tserebral'nom paraliche